From Name:
From Email:
To Name:
To Email:

Optional Message:


Illinois' innovation to change how scientists treat MRSA

from BusinessWire via Morningstar

Startup company ImmuVen and the University of Illinois Urbana-Champaign have entered into a license agreement under which ImmuVen will develop modified T cell receptor proteins for the purpose of treating cancer and methicillin-resistant Staphylococcus aureus (MRSA). ImmuVen was co-founded by David Kranz, Ph.D., of the University of Illinois Urbana-Champaign and Patrick Schlievert, Ph.D., of the University of Minnesota. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063